AdAlta

next generation protein therapeutics

i-bodies – a new class of protein therapeutics to treat human disease

AGM November 2017

Sam Cobb, CEO and Managing Director

AdAlta Limited (ASX:1AD)

s.cobb@adalta.com.au

Disclaimer

Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

ADALTA 2017 AGM AGENDA

- Chairman introduction
- AGM formal proceedings
- CEO presentation

Corporate and investment summary

- A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
- **Investment highlights**
  - Initial focus on treating fibrosis – high unmet medical need
  - Advanced lead fibrosis drug candidate AD-114 with significant pre-clinical validation
  - Fully funded for phase 1 development of lead fibrosis drug and i-body pipeline
  - Orphan drug designation USA FDA
  - Early commercialisation potential
  - Experienced team with strong track record of drug development and ability to deliver

Financial position

Key Financial Details	
ASX code	1AD
Share price (10 November 2017)	AU$0.20
Market capitalisation	AU$20.3m
Shares on issue*	101,257,434
Escrowed shares (August 2018)	24,000,000
Options on issue	969,427
Current cash (30 September 17)	AU$6.87m
Trading range (since listing)	AU$0.325 to $0.165
Average daily volume	12,311

Major Shareholders	%
Yuuwa Capital LP	53.39
Platinum Asset Management	8.05
Citycastle Pty Ltd	5.25
La Trobe University	3.00
National Nominees Limited	2.14
Other shareholders	28.17
Total	100%



AdAlta

AD-114 efficacy and safety

- **Efficacy**
  - Lung: IPF
    - Animal models
    - Human IPF tissue
    - Biomarker assessments (Alfred Health & others)
  - Broad fibrotic application with demonstration in other animal models and human tissues
    - Eye: wet-AMD
    - Liver: NASH
    - Kidney: CKD
    - Skin: HT Scarring



- **Safety**
  - NHP studies:
    - PK: IV and SC
    - Dose range finder
    - Multi dosing studies
  - PK-PD assays developed demonstrating target engagement
  - Cytokine analysis (20 human blood donors)

Achievements over last 12 months

- Manufacturing agreement of AD-114 kicked off with Fuji
- Innovation Connection Grant with Alfred Health; a collaboration with local IPF clinicians to evaluate AD-114 as a biomarker
- Presented at a number of international conferences including Discovery on Target, Bio Europe, Biotech Showcase (JPMorgan), ARVO, Bioshares, IPF Summit
- Strengthened Board and SAB
- Orphan Drug Designation IPF USA FDA
- XL protein collaboration for half life extension technology for AD-114
- Crossbeta license deal of shark antibody for Alzheimer's treatment
- SIEF Grant for i-body pipeline development
- Fibrosis Symposium February 2017 bringing clinicians and investors together

Some of our FY17 media and analyst coverage

FINANCIAL REVIEW — NEWS WEBSITE OF THE YEAR

"Patersons readies ASX-hopeful, AdAlta"

STOCKHEAD

"AdAlta hopes to take a bite out of fibrosis market with shark-based drug"

The Sydney Morning Herald

"Breakthrough for local biotech as influential backer emerges"

NDF RESEARCH
Providing independent research coverage of ASX-listed Life Science companies

"I-bodies continue to make progress"

news.com.au

"AdAlta on track for fibrosis treatment"

FierceBiotech

"'Shark antibody' biotech AdAlta seeks $7.5M IPO for fibrosis candidate"

LUNG DISEASE NEWS

"AdAlta presenting data on therapy candidate, AD-114 at inaugural IPF summit"

RT FOR DECISION MAKERS IN RESPIRATORY CARE

"Investigational IPF Drug Inspired by Shark Antibodies"

PATERSONS

"Ticking the right boxes on the way to the clinic"

Bioshares

"2017 Fibrosis Symposium"

Initiatives that drove awareness and engagement







- Fibrosis Symposium in February 2017 was well attended by investors and analysts, with follow up investor/analyst reports from Partersons, NDF Research and Bioshares
- Integrated campaigns for IPF awareness month across AdAlta's social channels (Twitter and LinkedIn) drove additional engagement around AD-114 and IPF
- New visitors to AdAlta website grew consistently throughout the period and LinkedIn channel grew significantly as driver of traffic to www.adalta.com.au

Financial operating results

- The Company reported a loss for the year ended 30 June 2017, after accounting for income tax benefit, of ($2,832,517) (30 June 2016: ($1,163,056)).
- The Company remains in a solid cash position with ~$6.87 million cash in the bank as at 30 September 2017
  - Closed IPO in August 2016, with oversubscribed offer, raising $10m to advance the lead i-body candidate AD-114 to the clinic for the treatment of IPF
  - Receipt of $ 1,777,030 R&D Tax Incentive 2017 ($738,208 2016), two Innovation Connections Grants for $100K, SIEF Grant $210K
  - Cost of services expense of $3,598,678 (30 June 2016: $1,413,975)
  - Employment benefit expense of $404,669 (30 June 2016: $224,620)
- The Company is in a strong and stable financial position to take AD-114 through to the end of Phase 1 trials in IPF

Management and Board in place to deliver strategy

Sam Cobb: Founding CEO and Director

Extensive experience in raising equity, contract and grant funding

15 years of commercialisation and management experience

Dr Paul MacLeman: Chairman

Director of CMAX Clinical Research Pty Ltd and Protec Groupe

Founded biologics companies, experienced ASX listed executive

Dr Robert Peach

Founder and CSO of Receptos Inc, acquired by Celgene Corporation in 2015 for US$7.8bn

Deep experience in research and drug development

Dr John Chiplin: Independent Director

CEO of investment Company NewStar Ventures

Managing Director of acquired antibody company Arana Therapeutics (acquired by Cephalon Inc. for US$200 million)

Liddy McCall & Dr James Williams: Yuuwa Capital Directors

Founders and investment Directors of Yuuwa Capital

Founders of iCeutica Inc (acquired 2011) and Dimerix Limited

Directors of several Australian biotech and Agritech companies

Multiple FDA, CE Mark and TGA approvals

Scientific Advisory Board

Internationally recognised with proven track record of drug development

Dr Mick Foley, AdAlta CSO

Expert in phage display

NIH, NHMRC, ARC, Gates funding and over 70 scientific publications

Brian Richardson: drug discovery and development expert

Ex-Sandoz and Novartis (40+ years), including Head of Pre-clinical Research

Over 60 original peer reviewed research papers

Steve Felstead: clinical advisor

Ex-Pfizer (25 years), including Head of Clinical Research, Pharmatherapeutics Division

Developed Zithromax, Vfend, Celsentri, Viagra

John Westwick: pulmonary drug discovery and development

Over 14 years experience at Novartis, head of respiratory drug discovery

Five product launches and 13 positive proof of concepts in respiratory, including a number of antibodies which are now in phase III.

David McGibney: pre-clinical and clinical advisor

20 years with Pfizer, including Head of European R&D

Ex Pfizer Ltd board member

Developed Viagra, and 10+ blockbuster drugs

AdAlta business model – strategy to create value



Market benchmarks

Fibrosis lead AD-114	adheron THERAPEUTICS Sep-15 acquired by Roche $105m + $475m milestones phase I asset	Promedior Aug-15 acquired by BMS $150m + $1.25b milestones phase IIa asset	Galecto Biotech AB Nov-14 acquired by BMS $444m phase I asset
Next gen antibodies	arGEN-X April-16 with Abbvie $40m upfront + $645m milestones & royalties	pieris PHARMACEUTICALS May -17 with AZ $58m upfront + $2.1b milestones & royalties	Ablynx July-17 with Sanofi €31m upfront + €2.4b milestones & royalties
GPCRs	HEPTARES therapeutics Acquired Feb-15 by Sosei $400m Phase Ib asset + 7 pre-clinical leads	receptos Acquired by Celgene July-15 $8b Ph III, Ph II and GPCR platform	Ablynx April-16 with Boehringer €8m payment for Ph1 GPCR nanobody + €125m milestones & royalties

IPF Phase II readouts generate $1.4billion market value

FibroGen

- (NASDAQ:FGEN)
- $869 million added to its market cap on announcement (7 August 2017) of meeting primary endpoint in Phase IIb study
- Pamrevlumab (FG-3019) 103 patients 48 weeks

Galápagos

- (Euronext:GLPG; NASDAQ:GLPG)
- $555 million added to market cap on announcement (9 August 2017) exploratory Phase IIa data
- FLORA trial had 23 IPF patients:17 drug, 6 placebo for 12 weeks

AD-114 development: key milestones



AdAlta

Expected newsflow next 12 months

H1 2017	✓	Orphan Drug Designation (US FDA)
	✓	Presentation at partnering meetings including Biotech Showcase 2017, San Francisco
	✓	Data available from AD-114 NASH animal studies
	✓	Manufactured material for toxicology testing available
H2 2017	✓	Strengthened eye fibrosis, funded by NHMRC Development Grant with Melbourne University, and lung data, funded by Innovation Connection Grant with Alfred Health
	✓	Completion of additional pre-clinical animal models in diseased of the lung, kidney, skin; strengthening broad anti-fibrotic data package of AD-114
	✓	AD-114 pharmacokinetics (half life) and toxicology results in 3 non-human primate studies
	✓	Presentation of AD-114 data at multiple fibrosis conferences
H1 2018	▶	Update on manufacturing
	▶	4 week NHP toxicology study
	▶	Publication of lung data and other key data with AD-114
H2 2018	▶	Phase I study with AD-114

AdAlta summary

- IPO August 2016 raised $10M to meet major milestones: phase I clinical trials of AD-114 in lung fibrosis and development of i-body pipeline
- Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need
- AD-114 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti-inflammatory effects as well as safety
- AD-114 orphan drug designation with FDA for treatment of IPF
- Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases

Early commercialisation opportunity, with experienced management and Board to drive AD-114 development and secure technology platform partnerships / product licensing deals